[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO2018006986A2 - Conjugado de acción prolongada del agonista triple receptor del glucagón /glp-1/gip - Google Patents

Conjugado de acción prolongada del agonista triple receptor del glucagón /glp-1/gip

Info

Publication number
CO2018006986A2
CO2018006986A2 CONC2018/0006986A CO2018006986A CO2018006986A2 CO 2018006986 A2 CO2018006986 A2 CO 2018006986A2 CO 2018006986 A CO2018006986 A CO 2018006986A CO 2018006986 A2 CO2018006986 A2 CO 2018006986A2
Authority
CO
Colombia
Prior art keywords
gip
glp
long
glucagon receptor
receptor agonist
Prior art date
Application number
CONC2018/0006986A
Other languages
English (en)
Inventor
Sung Youb Jung
Se Chang Kwon
Young Jin Park
Euh Lim Oh
Jong Suk Lee
Chang Ki Lim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CO2018006986A2 publication Critical patent/CO2018006986A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un conjugado de acción prolongada de un agonista triple que tiene actividades en cada uno del receptor de glucagón, GLP-1, y GIP, y uso del mismo.
CONC2018/0006986A 2015-12-31 2018-07-04 Conjugado de acción prolongada del agonista triple receptor del glucagón /glp-1/gip CO2018006986A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150191082 2015-12-31
KR20160163737 2016-12-02
PCT/KR2016/015555 WO2017116205A1 (ko) 2015-12-31 2016-12-30 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체

Publications (1)

Publication Number Publication Date
CO2018006986A2 true CO2018006986A2 (es) 2018-07-10

Family

ID=59225193

Family Applications (2)

Application Number Title Priority Date Filing Date
CONC2018/0006986A CO2018006986A2 (es) 2015-12-31 2018-07-04 Conjugado de acción prolongada del agonista triple receptor del glucagón /glp-1/gip
CONC2018/0006982A CO2018006982A2 (es) 2015-12-31 2018-07-04 Agonista triple de receptores de glucagón/glp-1/gip

Family Applications After (1)

Application Number Title Priority Date Filing Date
CONC2018/0006982A CO2018006982A2 (es) 2015-12-31 2018-07-04 Agonista triple de receptores de glucagón/glp-1/gip

Country Status (32)

Country Link
US (6) US10370426B2 (es)
EP (3) EP3398961B1 (es)
JP (5) JP6712323B2 (es)
KR (8) KR20170080522A (es)
CN (6) CN108699125B (es)
AU (4) AU2016382394B2 (es)
BR (2) BR112018013525A2 (es)
CA (2) CA3010182A1 (es)
CL (6) CL2018001776A1 (es)
CO (2) CO2018006986A2 (es)
CR (2) CR20180381A (es)
DK (1) DK3398961T3 (es)
DO (2) DOP2018000157A (es)
EA (2) EA038524B1 (es)
EC (2) ECSP18053053A (es)
ES (1) ES2925098T3 (es)
HK (2) HK1255834A1 (es)
HR (1) HRP20220995T1 (es)
HU (1) HUE059737T2 (es)
IL (2) IL260318B2 (es)
MX (2) MX2018008128A (es)
PE (1) PE20181494A1 (es)
PH (2) PH12018501411A1 (es)
PL (1) PL3398961T3 (es)
PT (1) PT3398961T (es)
RS (1) RS63541B1 (es)
SA (2) SA518391891B1 (es)
SG (2) SG11201805586SA (es)
TN (2) TN2018000228A1 (es)
TW (4) TW202330585A (es)
WO (2) WO2017116205A1 (es)
ZA (2) ZA201804998B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
SG11201608120TA (en) * 2014-03-31 2016-11-29 Hanmi Pharm Ind Co Ltd Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
SG11201705376SA (en) 2014-12-30 2017-08-30 Hanmi Pharm Ind Co Ltd Glucagon derivative having improved stability
UY36759A (es) 2015-06-30 2017-01-31 Hanmi Pharm Ind Co Ltd Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CR20180381A (es) 2015-12-31 2019-01-14 Hanmi Pharm Ind Co Ltd Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip
MY190855A (en) 2016-06-29 2022-05-12 Hanmi Pharma Co Ltd Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
TW201831207A (zh) 2017-02-03 2018-09-01 南韓商韓美藥品股份有限公司 生理活性物質之長效接合物及其用途
KR20180091773A (ko) 2017-02-07 2018-08-16 한미약품 주식회사 비펩티드성 중합체 링커 화합물, 그 링커 화합물을 포함하는 결합체, 및 이들의 제조방법
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
TWI810937B (zh) 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
CN109239346B (zh) * 2018-10-31 2019-10-11 中国药科大学 一组代谢标志物在代谢综合征早期诊断方面的应用
KR20200078413A (ko) * 2018-12-21 2020-07-01 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물
WO2020167010A1 (ko) 2019-02-15 2020-08-20 한미정밀화학주식회사 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법
WO2020214012A1 (ko) * 2019-04-19 2020-10-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법
WO2020214013A1 (ko) * 2019-04-19 2020-10-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 고지혈증에 대한 치료적 용도
CN111944055B (zh) * 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
EP4311578A3 (en) * 2019-06-28 2024-04-10 Hanmi Pharm. Co., Ltd. Triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors for treating liver disease
KR20220035199A (ko) 2019-08-19 2022-03-21 일라이 릴리 앤드 캄파니 인크레틴 유사체의 제조 방법
KR20210040818A (ko) * 2019-10-04 2021-04-14 한미약품 주식회사 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도
EP4058047A1 (en) 2019-11-11 2022-09-21 Boehringer Ingelheim International GmbH Npy2 receptor agonists
AR120714A1 (es) 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
CN111040022B (zh) * 2019-12-23 2021-12-14 万新医药科技(苏州)有限公司 针对胰高血糖素样肽-1受体、胰高血糖素受体、以及抑胃肽受体的三重激动剂
EP4085077A4 (en) 2019-12-31 2024-01-17 Beijing QL Biopharmaceutical Co., Ltd. FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF
US20230118307A1 (en) * 2020-01-13 2023-04-20 Hanmi Pharm. Co., Ltd. Therapeutic use of long-acting conjugate of triple agonist having activities to all of glucagon/glp-1/gip receptors for lung disease
EP4097099B1 (en) 2020-02-07 2024-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CA3174423A1 (en) * 2020-04-20 2021-10-28 Hanmi Pharm. Co., Ltd. Composition for prevention or treatment of hyperlipidemia comprising trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof and method using the same
KR20210144609A (ko) * 2020-05-22 2021-11-30 한미약품 주식회사 글루카곤, glp-1 및 gip 삼중 활성체의 지속형 결합체의 액상 제제
JP2023535382A (ja) * 2020-07-17 2023-08-17 ハンミ ファーマシューティカル カンパニー リミテッド 三重作用性持続型結合体又は三重作用剤を含む組合せ物の治療学的用途
CA3190163A1 (en) 2020-08-06 2022-02-10 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
IL300239A (en) 2020-08-07 2023-03-01 Boehringer Ingelheim Int Soluble NPY2 receptor agonists
AU2021326369A1 (en) * 2020-08-14 2023-02-23 Hanmi Pharm. Co., Ltd. Hypotensive pharmaceutical composition comprising triple activator having activity for all of glucagon, GLP-1, and GIP receptors
EP4197560A1 (en) * 2020-08-14 2023-06-21 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising a triple-activator persistent conjugate as active ingredient
JP2023543042A (ja) * 2020-09-25 2023-10-12 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体またはその結合体を含む骨疾患に対する予防または治療用薬学的組成物
US20230355789A1 (en) * 2020-09-25 2023-11-09 Hanmi Pharm. Co., Ltd. Therapeutic use, for neurodegenerative diseases, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof
US20230372448A1 (en) * 2020-09-25 2023-11-23 Hanmi Pharm. Co., Ltd. Therapeutic use of long-acting conjugate of triple agonist acting on all of glucagon, glp-1 and gip receptors against multiple sclerosis
CN115925995A (zh) 2020-09-30 2023-04-07 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
WO2022080985A1 (ko) * 2020-10-16 2022-04-21 한미약품 주식회사 Gip 유도체 또는 이의 지속형 결합체를 포함하는 루푸스-관련 질환의 예방 또는 치료용 약학적 조성물
EP4230220A4 (en) * 2020-10-16 2024-10-23 Hanmi Pharmaceutical Co Ltd USE OF A TRIPLE ACTIVATOR HAVING ACTIVITY ON ALL GLUCAGON, GLP-1 AND GIP RECEPTORS FOR THE TREATMENT OF THE SEQUELAE OF AN INFECTIOUS RESPIRATORY DISEASE
US20230381333A1 (en) * 2020-10-16 2023-11-30 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating vasculitis
US20230381331A1 (en) * 2020-10-16 2023-11-30 Hanmi Pharm. Co., Ltd. Gip derivative, long-acting conjugate thereof, and pharmaceutical composition comprising same
EP4230219A1 (en) * 2020-10-16 2023-08-23 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating lupus-related diseases
JP2023550594A (ja) 2020-10-30 2023-12-04 ノヴォ ノルディスク アー／エス Ｇｌｐ－１、ｇｉｐ、およびグルカゴン受容体三重作動薬
MX2023006419A (es) * 2020-12-02 2023-08-15 Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd Compuestos polipéptidos modificados con lactama.
CN116635050A (zh) 2020-12-24 2023-08-22 韩美药品株式会社 对胰高血糖素、glp-1和gip受体全部具有活性的新型三重激动剂及其用途
WO2022164222A2 (ko) * 2021-01-29 2022-08-04 한미약품 주식회사 Gip 유도체 또는 이의 지속형 결합체를 포함하는 폐질환의 예방 또는 치료용 약학적 조성물
JP2024523949A (ja) 2021-05-26 2024-07-04 ザ ユナイテッド バイオテクノロジー（ヘンチン）シーオー．，エルティーディー． マルチアゴニストおよびその使用
KR20230004135A (ko) * 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
TW202313667A (zh) * 2021-07-30 2023-04-01 大陸商南京明德新藥研發有限公司 含內醯胺橋的多肽化合物
KR20230095665A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 약물 및 이의 용도
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
TW202404997A (zh) * 2022-05-27 2024-02-01 韓商Ｄ＆Ｄ製藥科技股份有限公司 肽組合物及其使用方法
WO2024136573A1 (ko) * 2022-12-23 2024-06-27 한미약품 주식회사 신규한 glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 비만의 예방 또는 치료용 약학적 조성물
US20240270821A1 (en) 2023-01-31 2024-08-15 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5476304A (en) 1977-11-29 1979-06-18 Tokyo Printing Ink Mfg Co Ltd Ink
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
ES2321439T3 (es) * 2000-06-16 2009-06-05 ELI LILLY & COMPANY Analogos del peptido-1 similar a glucagon.
AU2002317599B2 (en) * 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
NZ541534A (en) * 2003-03-19 2008-05-30 Lilly Co Eli Polyethelene glycol link glp-1 compounds
JP2007537981A (ja) * 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
DK2256134T3 (en) 2003-11-13 2014-02-24 Hanmi Science Co Ltd IgG Fc fragment to a drug carrier and process for preparation thereof
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
CA2800389A1 (en) * 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compounds
WO2007124045A2 (en) * 2006-04-20 2007-11-01 Ampla Pharmaceuticals, Inc. Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
SG177953A1 (en) 2007-01-05 2012-02-28 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
BRPI0813139A8 (pt) 2007-06-19 2019-01-29 Glytech Inc peptídeo glp-1 com adição de cadeia oligossacarídea
CN101868476B (zh) 2007-09-05 2015-02-25 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
AU2009210570B2 (en) 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
CN102088989B (zh) 2008-06-17 2014-11-26 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
WO2010011439A2 (en) 2008-06-17 2010-01-28 Indiana University Research And Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
EA019203B9 (ru) * 2008-06-17 2014-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты глюкагонового рецептора/glp-1-рецептора
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
MX342409B (es) 2010-01-20 2016-09-28 Zealand Pharma As Tratamiento de enfermedades cardiacas.
US8551946B2 (en) * 2010-01-27 2013-10-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
JP5812627B2 (ja) * 2010-03-10 2015-11-17 公益財団法人相模中央化学研究所 改良Ｆｃ受容体およびその製造方法
JP6054861B2 (ja) 2010-03-26 2016-12-27 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
JP6050746B2 (ja) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
KR102497726B1 (ko) 2011-05-18 2023-02-07 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
ES2875748T3 (es) 2011-06-10 2021-11-11 Hanmi Science Co Ltd Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de la obesidad que los comprende
RS58606B1 (sr) 2011-06-17 2019-05-31 Hanmi Science Co Ltd Konjugat koji sadrži oksintomodulin i imunoglobulinski fragment, i njegova upotreba
JP6184404B2 (ja) * 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプターコアゴニスト
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
CN103957927B (zh) 2011-11-17 2016-11-09 印第安纳大学研究及科技有限公司 呈现糖皮质激素受体活性的胰高血糖素超家族肽
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
WO2013192131A1 (en) * 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
EP2864351B1 (en) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
DK2864350T3 (en) * 2012-06-21 2018-05-28 Univ Indiana Res & Tech Corp ANALOGUE OF GLUCAGON EXPRESSING GIP RECEPTOR ACTIVITY
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
EP2916819B1 (en) 2012-11-06 2019-07-10 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
AU2013347975B2 (en) 2012-11-20 2018-07-26 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
EP2922877B1 (en) * 2012-11-20 2018-09-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
SG11201504215PA (en) * 2012-12-21 2015-06-29 Sanofi Sa Functionalized exendin-4 derivatives
JP2016521253A (ja) * 2013-03-15 2016-07-21 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 持続性作用を有するプロドラッグ
CA2909581A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EP3033355A1 (en) 2013-08-16 2016-06-22 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN108271356A (zh) * 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
SG11201705376SA (en) 2014-12-30 2017-08-30 Hanmi Pharm Ind Co Ltd Glucagon derivative having improved stability
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
UY36759A (es) 2015-06-30 2017-01-31 Hanmi Pharm Ind Co Ltd Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
TW201718629A (zh) 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
JP6989503B2 (ja) 2015-12-02 2022-01-05 ハンミ ファーマシューティカル カンパニー リミテッド 脂肪酸誘導体を用いたタンパク質結合体及びその製造方法
CR20180381A (es) 2015-12-31 2019-01-14 Hanmi Pharm Ind Co Ltd Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip

Also Published As

Publication number Publication date
TWI731015B (zh) 2021-06-21
SG11201805586SA (en) 2018-07-30
KR102179391B1 (ko) 2020-11-16
BR112018013530A2 (pt) 2018-12-04
IL260310B2 (en) 2024-02-01
DOP2018000159A (es) 2018-09-30
EP3398962A1 (en) 2018-11-07
EP3398961B1 (en) 2022-06-29
KR102285378B1 (ko) 2021-08-04
HK1258177A1 (zh) 2019-11-08
EP3398962A4 (en) 2019-08-07
PT3398961T (pt) 2022-09-05
RS63541B1 (sr) 2022-09-30
CL2022000557A1 (es) 2022-09-23
JP2020171287A (ja) 2020-10-22
NZ744306A (en) 2024-05-31
CL2018001776A1 (es) 2018-08-10
NZ744321A (en) 2024-04-26
PE20181494A1 (es) 2018-09-18
WO2017116204A1 (ko) 2017-07-06
ZA201804998B (en) 2019-05-29
EP3398961A4 (en) 2019-06-12
TN2018000228A1 (en) 2019-10-04
HUE059737T2 (hu) 2022-12-28
US10981967B2 (en) 2021-04-20
KR102285377B1 (ko) 2021-08-04
ECSP18053055A (es) 2018-07-31
CN115920077A (zh) 2023-04-07
ES2925098T3 (es) 2022-10-13
AU2016382394B2 (en) 2019-07-04
CN116063453A (zh) 2023-05-05
KR20190105542A (ko) 2019-09-17
US20210188937A1 (en) 2021-06-24
SG11201805573RA (en) 2018-07-30
AU2016382393A1 (en) 2018-08-02
WO2017116205A1 (ko) 2017-07-06
CN109071624B (zh) 2023-01-17
SA518391891B1 (ar) 2021-07-12
CA3010182A1 (en) 2017-07-06
JP7030894B2 (ja) 2022-03-07
KR20200095436A (ko) 2020-08-10
KR102179392B1 (ko) 2020-11-16
TWI800478B (zh) 2023-05-01
ECSP18053053A (es) 2018-07-31
KR102367997B1 (ko) 2022-03-02
KR102401869B1 (ko) 2022-05-25
CR20180381A (es) 2019-01-14
TW202330585A (zh) 2023-08-01
JP2019504057A (ja) 2019-02-14
ZA201804997B (en) 2019-05-29
CN109071624A (zh) 2018-12-21
IL260318A (en) 2018-08-30
AU2019203888B2 (en) 2021-05-13
PH12018501411A1 (en) 2019-04-08
BR112018013525A2 (pt) 2018-12-04
KR20170080522A (ko) 2017-07-10
CA3010265A1 (en) 2017-07-06
IL260318B2 (en) 2024-02-01
US10370426B2 (en) 2019-08-06
US20220213164A1 (en) 2022-07-07
PH12018501409A1 (en) 2019-04-08
CO2018006982A2 (es) 2018-07-10
EA038544B1 (ru) 2021-09-13
CL2020002033A1 (es) 2020-10-09
JP7526039B2 (ja) 2024-07-31
TW201737945A (zh) 2017-11-01
US20190002520A1 (en) 2019-01-03
HRP20220995T1 (hr) 2022-11-11
JP6712322B2 (ja) 2020-06-17
AU2019203888A1 (en) 2019-06-20
CL2018001795A1 (es) 2018-08-10
US10400020B2 (en) 2019-09-03
EA038524B1 (ru) 2021-09-09
US20180311315A1 (en) 2018-11-01
CN116063454A (zh) 2023-05-05
KR20200096184A (ko) 2020-08-11
MX2018008128A (es) 2018-12-06
EP3985017A1 (en) 2022-04-20
TWI807580B (zh) 2023-07-01
KR20190104958A (ko) 2019-09-11
AU2016382394A1 (en) 2018-08-02
IL260318B1 (en) 2023-10-01
AU2019203891A1 (en) 2019-06-20
TN2018000231A1 (en) 2019-10-04
SA518391903B1 (ar) 2022-08-01
DK3398961T3 (da) 2022-08-22
AU2016382393B2 (en) 2019-07-04
KR20190060749A (ko) 2019-06-03
HK1255834A1 (zh) 2019-08-30
KR20190062344A (ko) 2019-06-05
CN116059389A (zh) 2023-05-05
EA201891360A1 (ru) 2018-12-28
JP6712323B2 (ja) 2020-06-17
TW201730207A (zh) 2017-09-01
JP2022130723A (ja) 2022-09-06
CN108699125B (zh) 2022-10-28
CR20180380A (es) 2018-12-07
US20190218269A1 (en) 2019-07-18
JP2019504055A (ja) 2019-02-14
IL260310A (en) 2018-08-30
CN108699125A (zh) 2018-10-23
EP3398961A1 (en) 2018-11-07
JP2020128428A (ja) 2020-08-27
KR20170080521A (ko) 2017-07-10
US20190153060A1 (en) 2019-05-23
IL260310B1 (en) 2023-10-01
TW202216748A (zh) 2022-05-01
CL2020002034A1 (es) 2020-10-09
AU2019203891B2 (en) 2021-05-13
PL3398961T3 (pl) 2022-09-26
DOP2018000157A (es) 2018-10-15
MX2018008027A (es) 2018-11-29
US11332508B2 (en) 2022-05-17
EA201891359A1 (ru) 2019-01-31
CL2022000558A1 (es) 2022-09-23

Similar Documents

Publication Publication Date Title
CO2018006986A2 (es) Conjugado de acción prolongada del agonista triple receptor del glucagón /glp-1/gip
CL2023000198A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
CL2018003045A1 (es) Semaglutida en afecciones cardiovasculares.
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
MX2020003217A (es) Coagonistas de accion prolongada de los receptores de glucagon y glp-1.
PH12018501844A1 (en) Liraglutide in cardiovascular conditions
MY199261A (en) Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist